Basel, July 21, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis had a strong quarter for innovation, with US approval and launch of both Entresto and Glatopa being key highlights. Additionally, we reported a broad range of positive clinical data across franchises, including Tafinlar/Mekinist in metastatic melanoma and Cosentyx in ankylosing spondylitis. We are confident we will deliver on our priorities for the year, and confirm our full-year guidance.”
- Sales, core[1] operating income and core EPS grew …